Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lepri

Showing results (621-630 of 959) with videos related to

Pageof 96
Sort By:
Brazilian Oral Research|February 19, 2021
Influence of Er,Cr:YSGG laser on root dentin submitted to erosive and/or abrasive challengesGabriella Rodovalho Paiva, Regina Guenka Palma Dibb, Juliana Jendiroba Faraoni, et al.
HIV Medicine|April 28, 2025
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohortAndrea De Vito, Alessandro Tavelli, Alessandro Cozzi-Lepri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 13, 2005
Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients studyRita Murri, Alessandro Cozzi Lepri, Paola Cicconi, et al.
HIV Clinical Trials|March 2, 2018
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort<sup/>Antonella d'Arminio Monforte, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
HIV Clinical Trials|November 14, 2018
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patientsChiara Dentone, Antonio Di Biagio, Alessandro Cozzi Lepri, et al.
Antiviral Therapy|June 25, 2008
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological responseKoen Deforche, Alessandro Cozzi-Lepri, Kristof Theys, et al.
AIDS (London, England)|August 30, 2008
Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophyBarbara Zanone Poma, Agostino Riva, Milena Nasi, et al.
Journal of Medical Virology|October 26, 2006
Significant link between sCD30 changes and HIV viremia in patients treated with HAARTPriscilla Biswas, Alessandro Cozzi-Lepri, Fanny Delfanti, et al.
BMC Infectious Diseases|June 12, 2021
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIVEsther Merlini, Alessandro Cozzi-Lepri, Antonella Castagna, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|August 1, 2022
Diosgenin increases BBC3 expression in HepG2/C3A cells and alters cell communication in a 3D spheroid modelMatheus Felipe da Silva, Luan Vitor Alves de Lima, Thalita Alves Zanetti, et al.
Pageof 96

Showing results (621-630 of 959) with videos related to

Sort By:
Pageof 96
Brazilian Oral Research|February 19, 2021
Influence of Er,Cr:YSGG laser on root dentin submitted to erosive and/or abrasive challengesGabriella Rodovalho Paiva, Regina Guenka Palma Dibb, Juliana Jendiroba Faraoni, et al.
HIV Medicine|April 28, 2025
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohortAndrea De Vito, Alessandro Tavelli, Alessandro Cozzi-Lepri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 13, 2005
Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients studyRita Murri, Alessandro Cozzi Lepri, Paola Cicconi, et al.
HIV Clinical Trials|March 2, 2018
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort<sup/>Antonella d'Arminio Monforte, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
HIV Clinical Trials|November 14, 2018
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patientsChiara Dentone, Antonio Di Biagio, Alessandro Cozzi Lepri, et al.
Antiviral Therapy|June 25, 2008
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological responseKoen Deforche, Alessandro Cozzi-Lepri, Kristof Theys, et al.
AIDS (London, England)|August 30, 2008
Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophyBarbara Zanone Poma, Agostino Riva, Milena Nasi, et al.
Journal of Medical Virology|October 26, 2006
Significant link between sCD30 changes and HIV viremia in patients treated with HAARTPriscilla Biswas, Alessandro Cozzi-Lepri, Fanny Delfanti, et al.
BMC Infectious Diseases|June 12, 2021
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIVEsther Merlini, Alessandro Cozzi-Lepri, Antonella Castagna, et al.
Mutation Research. Genetic Toxicology and Environmental Mutagenesis|August 1, 2022
Diosgenin increases BBC3 expression in HepG2/C3A cells and alters cell communication in a 3D spheroid modelMatheus Felipe da Silva, Luan Vitor Alves de Lima, Thalita Alves Zanetti, et al.
Pageof 96